A minuscule, biodegradable scaffold has been created to transplant stem cells and deliver drugs within the body, the Nature Communications journal has reported, which could help with treatments for Alzheimer’s and Parkinson’s diseases, as well as aging brain degeneration and spinal cord injuries.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
We spoke to Dr. David R. Hillyard MD, Chair and Medical Director of Molecular Infectious Diseases at ARUP Laboratories, about his work within the realm of infectious diseases and the increasing role of molecular diagnostics in combating pathogens.
We spoke to Dr. Carlos Prada, Assistant Professor of Clinical Genetics at Cincinnati Children’s Hospital Medical Center within the University of Cincinnati Department of Pediatrics, and Dr. Emma Clement, Consultant in Clinical Genetics at Great Ormond Street Hospital in the UK, to find out how more about the challenges of implementing NGS globally, and where that implementation has been successful.
AMP 2018: Decoding the Cancer Genome: Breakthrough AI Technology Quickly Identifies Actionable Mutations
Explosive advances in next-generation sequencing (NGS) have greatly improved the ability to identify actionable cancer mutations, both for solid and hematological malignancies, and sparked a new era of oncology care. But accurate analysis and proper interpretation of the complex genomic data produced by NGS remain key hurdles.
The Association for Molecular Pathology (AMP) Annual Meeting & Expo is where the molecular diagnostics community gathers to advance clinical knowledge, discuss new discoveries, share recent successes, and showcase the latest technological advances in molecular medicine.
Every single cell in the human body could contain a cancer “kill code” set to destroy cells which become cancerous, a new study reported in Nature Communications. The study, conducted by Northwestern University in the US, found that cancer cannot become resistant to this code, making it a potentially incredibly effective treatment.
Cells settling in an organ other than the correct one during embryogenesis are often the cause of rare ovarian and pancreatic cancers which affect only young women, researchers at the University of Geneva (UNIGE) and the University Hospitals of Geneva (HUG) have found.
Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service.
A new report from the University of Pennsylvania School of Veterinary Medicine has expanded what we know about the connection between myeloid-derived immunosuppressor cells (MDSCs) and aggressive disease. Their research has found that blocking the deltaNp63 protein on tumour cells which directs MDSCs to tumour and metastatic sites, or blocking the MDSCs themselves, reduces tumour growth and metastasis in a mouse model of triple-negative breast cancer (TNBC).
Independent US Food and Drug Administration (FDA) advisors unanimously backed Celltrion’s new Rituxan biosimilar recently, potentially allowing the company to threaten the sales dominance of Roche’s top drug.
For the first time, scientists have performed prenatal gene editing to prevent a lethal metabolic disorder in laboratory animals, offering the potential to treat human congenital diseases before birth.